ATE215829T1 - Die verwendung von heparin oder heparansulfat kombiniert mit chitosan zur vorbeugung oder behandlung von infektionen verursacht durch den herpes-virus - Google Patents
Die verwendung von heparin oder heparansulfat kombiniert mit chitosan zur vorbeugung oder behandlung von infektionen verursacht durch den herpes-virusInfo
- Publication number
- ATE215829T1 ATE215829T1 AT97934838T AT97934838T ATE215829T1 AT E215829 T1 ATE215829 T1 AT E215829T1 AT 97934838 T AT97934838 T AT 97934838T AT 97934838 T AT97934838 T AT 97934838T AT E215829 T1 ATE215829 T1 AT E215829T1
- Authority
- AT
- Austria
- Prior art keywords
- heparin
- chitosan
- herpes virus
- prevent
- infections caused
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9602931A SE507028C2 (sv) | 1996-08-06 | 1996-08-06 | Ny medicinsk användning |
| PCT/SE1997/001320 WO1998005341A1 (en) | 1996-08-06 | 1997-08-01 | The use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE215829T1 true ATE215829T1 (de) | 2002-04-15 |
Family
ID=20403528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97934838T ATE215829T1 (de) | 1996-08-06 | 1997-08-01 | Die verwendung von heparin oder heparansulfat kombiniert mit chitosan zur vorbeugung oder behandlung von infektionen verursacht durch den herpes-virus |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6207653B1 (de) |
| EP (1) | EP0930885B1 (de) |
| JP (1) | JP2000515543A (de) |
| CN (1) | CN1227493A (de) |
| AT (1) | ATE215829T1 (de) |
| AU (1) | AU705189B2 (de) |
| CA (1) | CA2261742A1 (de) |
| DE (1) | DE69711897T2 (de) |
| DK (1) | DK0930885T3 (de) |
| ES (1) | ES2174273T3 (de) |
| NZ (1) | NZ333925A (de) |
| SE (1) | SE507028C2 (de) |
| WO (1) | WO1998005341A1 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE508760C2 (sv) | 1997-04-29 | 1998-11-02 | Medicarb Ab | Användning av en komposition innefattande kitosan i kombination med en polysackarid, som aktiv komponent i ett lösningsmedel, för framställning av ett spendoppningsmedel för mjölkproducerande djur |
| US6977248B1 (en) * | 1999-08-25 | 2005-12-20 | Massachusetts Institute Of Technology | Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry |
| AU7070700A (en) * | 1999-08-25 | 2001-03-19 | Massachusetts Institute Of Technology | Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry |
| US20020119949A1 (en) * | 2001-02-26 | 2002-08-29 | Asa Hellman | Prophylactic teat treatment |
| US7968122B2 (en) * | 2003-12-10 | 2011-06-28 | Adventrx Pharmaceuticals, Inc. | Anti-viral pharmaceutical compositions |
| EP1774971A1 (de) * | 2005-10-14 | 2007-04-18 | Advanced in Vitro Cell Technologies, S.L. | Nanopartikel enthaltend Chitosan und Heparin |
| MX344592B (es) | 2005-12-13 | 2016-12-20 | Exthera Medical Corp | Metodo para eliminar extracorporalmente de la sangre un microbio patogeno, una celula inflamatoria o una proteina inflamatoria. |
| WO2008155683A1 (en) | 2007-06-18 | 2008-12-24 | Firmenich Sa | Malodor counteracting compositions and method for their use |
| CL2008000156A1 (es) * | 2008-01-18 | 2008-08-01 | Igloo Zone Chile S A | Gel estable hidrofilo en base a un polimero para aplicacion topica porque comprende quitosano disuelto en un solvente; proceso para obtener el gel para uso topico antes mencionado; uso del gel. |
| CA2763092A1 (en) * | 2009-06-10 | 2010-12-16 | Exthera Ab | Use of a composition for the treatment of mucositis |
| AU2010326028B2 (en) | 2009-12-01 | 2014-10-02 | Exthera Medical Corporation | Method for removing cytokines from blood with surface immobilized polysaccharides |
| US20110212181A1 (en) * | 2010-02-26 | 2011-09-01 | The University Of Hong Kong | Compositions and methods for treating chronic respiratory inflammation |
| CN102858950A (zh) * | 2010-04-07 | 2013-01-02 | 三菱瓦斯化学株式会社 | 保存稳定性优异的含有s-腺苷-l-蛋氨酸的干酵母组合物及其制造方法 |
| JPWO2011142484A1 (ja) * | 2010-05-14 | 2013-07-22 | 株式会社日本触媒 | ポリアルキレンイミンを含むウイルス感染症治療薬 |
| WO2012112724A1 (en) | 2011-02-15 | 2012-08-23 | Exthera Medical, Llc | Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines |
| WO2013188073A1 (en) | 2012-06-13 | 2013-12-19 | Exthera Medical, Llc | Use of heparin and carbohydrates to treat cancer |
| WO2014209782A1 (en) | 2013-06-24 | 2014-12-31 | Exthera Medical Corporation | Blood filtration system containing mannose coated substrate |
| BR112016009827B1 (pt) | 2013-11-08 | 2021-10-26 | Exthera Medical Corporation | Método in vitro para concentrar patógenos infecciosos presentes em uma amostra biológica obtida a partir de um indivíduo sob suspeita de estar infectado com os ditos patógenos, concentrador e kit |
| JP2017513636A (ja) | 2014-04-24 | 2017-06-01 | エクスセラ メディカル コーポレイション | 高流量を用いて血液から細菌を除去するための方法 |
| MX2017003723A (es) | 2014-09-22 | 2017-06-30 | Exthera Medical Corp | Dispositivo de hemoperfusion portatil. |
| WO2017151797A1 (en) | 2016-03-02 | 2017-09-08 | Exthera Medical Corporation | Method for treating drug intoxication |
| US11911551B2 (en) | 2016-03-02 | 2024-02-27 | Exthera Medical Corporation | Method for treating drug intoxication |
| US20230381217A1 (en) * | 2020-10-14 | 2023-11-30 | Medoderm Gmbh | Liquid composition for use in the prevention or reduction of skin irritation, allergy and/or an infectious disease |
| WO2023044132A2 (en) * | 2021-09-17 | 2023-03-23 | Shawn Walker | Use of chitosan complexes or compositions to reduce infiltration of environmental factors into the brain |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU77562A1 (de) * | 1977-06-17 | 1979-03-26 | Ciba Geigy Ag | Verfahren zur herstellung von neuen pharmazeutischen praeparaten |
| EP0240098A3 (de) | 1986-04-04 | 1989-05-10 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Oligo und Polysaccharide zur Behandlung von Krankheiten verursacht durch Retroviren |
| AU1052492A (en) | 1991-01-31 | 1992-08-06 | Farmitalia Carlo Erba S.R.L. | Synergistic composition comprising a fibroblast growth factor and a sulfated polylsaccharide, for use as antiviral agent |
-
1996
- 1996-08-06 SE SE9602931A patent/SE507028C2/sv not_active IP Right Cessation
-
1997
- 1997-08-01 AT AT97934838T patent/ATE215829T1/de not_active IP Right Cessation
- 1997-08-01 EP EP97934838A patent/EP0930885B1/de not_active Expired - Lifetime
- 1997-08-01 DE DE69711897T patent/DE69711897T2/de not_active Expired - Fee Related
- 1997-08-01 NZ NZ333925A patent/NZ333925A/xx unknown
- 1997-08-01 US US09/230,021 patent/US6207653B1/en not_active Expired - Fee Related
- 1997-08-01 CN CN97197038A patent/CN1227493A/zh active Pending
- 1997-08-01 DK DK97934838T patent/DK0930885T3/da active
- 1997-08-01 CA CA002261742A patent/CA2261742A1/en not_active Abandoned
- 1997-08-01 ES ES97934838T patent/ES2174273T3/es not_active Expired - Lifetime
- 1997-08-01 AU AU37911/97A patent/AU705189B2/en not_active Ceased
- 1997-08-01 JP JP10507859A patent/JP2000515543A/ja active Pending
- 1997-08-01 WO PCT/SE1997/001320 patent/WO1998005341A1/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP0930885A1 (de) | 1999-07-28 |
| SE9602931D0 (sv) | 1996-08-06 |
| AU705189B2 (en) | 1999-05-20 |
| AU3791197A (en) | 1998-02-25 |
| DE69711897D1 (de) | 2002-05-16 |
| EP0930885B1 (de) | 2002-04-10 |
| JP2000515543A (ja) | 2000-11-21 |
| ES2174273T3 (es) | 2002-11-01 |
| DK0930885T3 (da) | 2002-05-06 |
| DE69711897T2 (de) | 2002-08-22 |
| WO1998005341A1 (en) | 1998-02-12 |
| SE9602931L (sv) | 1998-02-07 |
| US6207653B1 (en) | 2001-03-27 |
| CA2261742A1 (en) | 1998-02-12 |
| NZ333925A (en) | 2000-07-28 |
| SE507028C2 (sv) | 1998-03-16 |
| CN1227493A (zh) | 1999-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE215829T1 (de) | Die verwendung von heparin oder heparansulfat kombiniert mit chitosan zur vorbeugung oder behandlung von infektionen verursacht durch den herpes-virus | |
| ATE266417T1 (de) | Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien | |
| DE69428268T2 (de) | Verwendung von lokalanaesthetika zur herstellung eines arzneimittels zur behandlung von bronchialasthma | |
| PT646012E (pt) | Cura de feridas e tratamento de perturbacoes fibroticas por tgfbeta-3 | |
| CA2194976A1 (en) | Wound healing agent | |
| BR9306040A (pt) | Tratamento e profilaxia de doenças provocadas por parasitos ou bactérias | |
| DE69327731D1 (de) | Verfahren zur herstellung einer schutzsperre gegen virus | |
| ATE94760T1 (de) | Sulfatierte vinylpolymere in praeparaten zur behandlung von retroviralen infektionen. | |
| DE69232911D1 (de) | Verwendung eines polyhydroxybenzamids oder dessen Derivat zur Herstellung eines Medikaments für die Behandlung von viralen Infektionen | |
| BR9406548A (pt) | Composto para emprego como produto farmacêutico composto para emprego no tratamento ou prevenção de câncer e pré-câncer ou de doenças causadas por infecçao viral composto para emprego no tratamento ou prãvençao de câncer ou de pré-câncer composto para emprego no tratamento ou prevenção de doenças causadas por infecção viral composiçao farmacêutica processo para tratar doenças causadas por infecção viral processo de tratamento de câncer ou pré-câncer composto de ácido clorobenzenossulfônico ou ni | |
| DE50100833D1 (de) | Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
| DE69003960D1 (de) | Die Verwendung von deacetyliertem Chitin zur Herstellung eines Medikamentes für die Behandlung von entzündliche Krankheiten. | |
| ATE316789T1 (de) | Verwendung von flupirtin zur prophylaxe und therapie von erkrankungen, die mit einer beeinträchtigung des hämatopoetischen zellsystems einhergehen | |
| DE69428112T2 (de) | Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen | |
| DE69623316T2 (de) | Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen | |
| ATE204476T1 (de) | Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazi e zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem | |
| DE69925312D1 (de) | Bupropion zur behandlung von viralen erkrankungen | |
| SE9303612D0 (sv) | New use | |
| ATE174507T1 (de) | Verwendung eines benzimidazolwurmmittels zur behandlung von mikrosporeninfektionen | |
| EP0342565A3 (de) | Verwendung des Thiazol-Derivates Tiprotimod zur Herstellung eines Mittels zur Therapie von Virusinfektionen | |
| ATE255417T1 (de) | Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen | |
| EP1143981A4 (de) | Behandlung und vorbeugung von hiv- und anderen virus infektionen | |
| DK120892D0 (da) | Treatment and prophylaxis of diseases caused by parasites, fungi or bacteria | |
| DE69210737D1 (de) | Verwendung von L-2-Oxothiazolidine-4-Carboxylate zur Herstellung eines Arzneimittels zur Behandlung von latenten HIV-Infektionen | |
| CA2147749A1 (en) | Therapeutic agent for diseases of periodontal tissue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |